Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of thermal ablation followed by toripalimab in unresectable hepatocellular carcinoma
ChiCTR2000039739Phase 2Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Progression-free survival and Disease control rate. Started Jun 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000039739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039739.